Friday, February 03, 2017 7:42:34 AM
properties Scenesse holds but this article underscores how likely the implant is to alleviate / cure MS and other neuro inflammatory diseases.
They even specify that they are indeed using Scenesse in the lab.
Dr. Wolgen is fully aware of this as per the AGM but we won't see Clinuvel pursue other indications than dermatology and UV-related disorders.
Licensing, however, seems more and more plausible.
http://stm.sciencemag.org/content/8/362/362ra146
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM